Oxidative stress as a cofactor in spinocerebellar ataxia type 2

References

• Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet 2004;3:291–304.
   PubMed Web of Science ®Google Scholar
• Velázquez PL, Santos FN, García ZR, Paneque HM, Hechevarria RR. Epidemiology of Cuban hereditary ataxia. Rev Neurol 2001;32:606–11.
   PubMed Web of Science ®Google Scholar
• Velázquez-Pérez L, Rodríguez-Labrada R, Canales-Ochoa N, Sánchez-Cruz G, Fernández-Ruiz J, Medrano J, et al. Progression markers of spinocerebellar ataxia 2. A twenty years neurophysiological follow up study. J Neurol Sci 2010;290:22–6.
   PubMed Web of Science ®Google Scholar
• Velásquez Pérez L, Almaguer Mederos L, Santos Falcón N, Hechavarria R, Sánchez Cruz G, Paneque HM. Spinocerebellar ataxia type 2 in Cuba. A study of the electrophysiological phenotype and its correlation with clinical and molecular variables. Rev Neurol 2001;33(12):1129–36.
   PubMed Web of Science ®Google Scholar
• Orozco DG, Estrada R, Perry T, Araña J, Fernández R. Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological and biochemical findings. J Neurol Sci 1989;93:37–50.
   PubMed Web of Science ®Google Scholar
• Pandolfo M. Drug insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol 2008;4(2):86–96.
   PubMedGoogle Scholar
• Diplock AT. Antioxidant and disease prevention. Mol Asp Med 1994;15:293–376.
   PubMed Web of Science ®Google Scholar
• Harding AE. Clinical features and classification of inherited ataxias. In: , Harding AE, Deufel T, (eds.) Inherited ataxias. New York: Raven; 1993. vol. 61. p. 1–14.
   Google Scholar
• Wadia N, Pang J, Desai J, Mankodi A, Desai M, Chamberlain S. A clinicogenetic analysis of six Indian spinocerebellar ataxia (SCA2) pedigrees. Brain 1998;121:2341–55.
   PubMed Web of Science ®Google Scholar
• Perretti A, Santoro L, Lanzillo B. Autosomal dominant cerebella ataxia type I: multimodal electrophysiological study and comparison between SCA1 and SCA2 patients. J Neurol Sci 1996;142:45–53.
   PubMed Web of Science ®Google Scholar
• Estrada R, Galárraga J, Orozco G, Nodarse A, Auburger G. Spinocerebellar ataxia 2 (SCA2):morphometric analyses in 11 autopsies. Acta Neuropathol 1999;97:306–10.
   PubMed Web of Science ®Google Scholar
• Lastres-Becker I, Rub U, Auburger G. Spinocerebellar ataxia 2 (SCA2). Cerebellum 2008;7(2):115–24.
   PubMed Web of Science ®Google Scholar
• Velazquez-Perez L, Seifried C, Santos-Falcon N, Abele M. Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol. 2004;56(3):444–7.
   PubMed Web of Science ®Google Scholar
• Sahnoun Z, Jamoussi K, Zeghal KM. Free radicals and antioxidants: human physiology, pathology and therapeutics aspects. Therapy 1997;52(4):251–70.
   Google Scholar
• Nonia D, Schmidt MH, van de Loo S, Eich F, Dikic I, Nowock J, et al. Ataxin 2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal 2008;20:1725–39.
   PubMed Web of Science ®Google Scholar
• Velazquez Perez L, Sanchez Cruz G, Canales Ochoa N, Rodriguez Labrada R. Electrophysiological features in patients and presymptomatic relatives with spinocerebellar ataxia type 2. J Neurol Sci 2007;263(1–2):158–64.
   PubMed Web of Science ®Google Scholar
• Rub U, Del Turco D, Burk K. Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. Neuropathol Appl Neurobiol 2005;31:127–40.
   PubMed Web of Science ®Google Scholar
• Maher P. Redox control of neural function: Background, mechanism, and significance. Ant Redox Signal 2006;8:1941–70.
   PubMed Web of Science ®Google Scholar
• Rao Muralikrishna R, Hatcher JF. Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. Ant Redox Signal 2010;12(1):125–69.
   PubMed Web of Science ®Google Scholar
• Carlson KM, Andersen JM, Orr TH. Emerging pathogenic pathways in the spinocerebellar ataxias. Curr Opin Genet Dev 2009;19:247–53.
   PubMed Web of Science ®Google Scholar
• Lloret A, Calzone R, Dunster C, Manini P, d'Ischia M, Degan P, et al. Different patterns of in vivo prooxidant states in a set of cancer or aging related genetic diseases. Free Rad Biol Med 2008;44:495–503.
   PubMed Web of Science ®Google Scholar
• Satterfield TF, Pallanck LJ. Ataxin 2 and its drosophila homolog ATX-2 physically assemble with polyribosomes. Hum Mol Genet 2006;15:2523–32.
   PubMed Web of Science ®Google Scholar
• Raiser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsh S. An integrative approach to gain insights into the cellular function of human ataxin 2. J Mol Biol 2005;346:203–14.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44–84.
   PubMed Web of Science ®Google Scholar
• Casetta V, Govoni , Granieri E. Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Des 2005;11:1–20 I.
   Google Scholar
• Grisham MB, McCord JM. Chemistry and cytotoxicity of reactive oxygen metabolites. In: , Taylor AE, Matalon S, Ward P, (eds.). Physiology of oxygen radicals. Bethesda, Maryland, American Physiological Society, Clinical Physiology Series Book, 316 pages, 1986. p. 1–18.
   Google Scholar
• Southorn PA, Powis G. Free radicals in medicine I. Chemical nature and biologic reactions. Clin Proc 1988;63:381–9.
   Google Scholar
• Matilla-Dueñas A, Sánchez I, Corral-Juan M, Dávalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum 2010;9:148–66.
   PubMed Web of Science ®Google Scholar
• Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 is not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 2000;26:44–50.
   PubMed Web of Science ®Google Scholar
• Aguiar J, Fernández J, Aguilar A, Mendoza Y, Vázquez M, Suárezd J, et al. Ubiquiyuos expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci Lett 2006;392:202–6.
   PubMed Web of Science ®Google Scholar
• Albrecht M, Golatta M, Wullner U, Lengauer T. Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem 2004;271:3155–70.
   PubMedGoogle Scholar
• Boesch SM, Schocke M, Burk K, Hollosi P, Fornai F, Aichner FT, et al. Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia 2 and 6. J Magn Reson Imaging 2001;13:553–9.
   PubMed Web of Science ®Google Scholar
• Boesch SM, Wolf C, Seppi K, Felber S, Wenning GK, Schocke M. Differentiation of SCA 2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging 2007;25(3):564–9.
   PubMed Web of Science ®Google Scholar
• Oz G, Hutter D, Tlac I, Clark B, Gross MD, Jiang H, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord 2010;25(9):1253–61.
   PubMed Web of Science ®Google Scholar
• Oz G, Iltis I, Hutter D, Thomas W, Busara KO, Gomez CM. Distinct neurochemical profiles of spinocerebellar ataxias 1,2,6 and cerbellar system atrophy. Cerebellum 2011;10(2):208–17.
   PubMed Web of Science ®Google Scholar
• Almaguer L, Almaguer D, Gonzáles Y, Martínez E, Valcárcel P. Capacidad antioxidante total de en pacientes cubanos con ataxia Espinocerebelosa tipo 2. Rev Mex Neuroci. 2005;6(3):201–6.
   Google Scholar
• Velázquez L, Sánchez G, García JC, Delgado R, Márquez L, Martínez E, et al. Spinocerebellar ataxia type 2 (sca-2) in Cuba. A study of the clinical electrophysiological and redox system variations and its correlation with CAG repeats. Rest Neurol Neurosci. 2003;20(6):277.
   Google Scholar
• Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AI. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 2008;15(12):1371–9.
   PubMed Web of Science ®Google Scholar
• Rustin P, Rotig A, Munnich A, Siddi D. Heart hypertrophy and function are improved by idebonone in Friderich's ataxia. Free Radic Res 2002;36:467–9.
   PubMed Web of Science ®Google Scholar
• Mariotti AO, Solari A, Torta D, Marano L, Fiorentini C, Di D. Idebenone treatment in Friedreich's Ataxia: one-year-long randomize placebo-controlled trial. Neurology 2003;60(10):1676–9.
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Baker A, Jeffries N, Fischebeck KH. Neurological effect of high-dose idebenone in patients with Friedreich's Ataxia: a randomize placebo-controlled trial. Lancet Neurol 2007;6(10):878–86.
   PubMed Web of Science ®Google Scholar
• Pineda M, Arpa J, Montero R, Aracil A, Dominguez F, Galvan M, et al. Idebenone treatment in paediatric and adult patients with Friedreich's Ataxia: long-term follow-up. Eur Paediatr Neurol 2008;12(6):470–5.
   PubMed Web of Science ®Google Scholar
• Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005;62:621–6.
   PubMedGoogle Scholar
• Reichenbach J, Schubert R, Schindler D, Muller K, Bohles HJ, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal 2002;4:465–9.
   PubMed Web of Science ®Google Scholar
• Gatei M, Shkedy D, Khanna KK, Uziel T, Shiloh Y, Pandita TK. Ataxia telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid. Oncogene 2001;20:289–94.
   PubMed Web of Science ®Google Scholar
• Aksoy Y, Sanal O, Metin A, Tezcan I, Ersoy F, Ogus H, et al. Antioxidant enzymes in red blood cells and lymphocytes of ataxia telangiectasia patients. Turk J Pedriatr 2004;46:204–7.
   PubMed Web of Science ®Google Scholar
• Marcelain K, Navarrete CL, Barvo M, Santos M, Be C, Pincheira J. Effect of vitamin E (DL alpha tocoperol) on the frequency of chromosomal damage in lymphocytes from patients with ataxia telangiectasia. Rev Med Chil 2002;130:957–63.
   PubMed Web of Science ®Google Scholar
• Browse SE, Roberts LJ, Dennery PA, Doctrow SR, Beal MF, Barlow C, et al. Treatment with catalytic antioxidant corrects the neurobehavioral defect in ataxia telangiectasia mice. Free Rad Biol Med 2004;36:938–42.
   PubMed Web of Science ®Google Scholar
• Reliene R, Fischer E, Schiest RH. Effects of N acetylcysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res 2004;64:5148–53.
   PubMed Web of Science ®Google Scholar
• Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, Russo A, et al. Cancer chemoprevention by the antioxidant Tempol in atm-deficient mice. Hum Mol Genet 2004;13:1793–802.
   PubMed Web of Science ®Google Scholar
• Velázquez-Pérez L, Rodríguez-Labrada R, García-Rodríguez JC, Almaguer-Mederos LE, Cruz-Mariño T, Laffita-Mesa JM. A comprehensive review of spinocerebellar ataxia type 2 in Cuba. Cerebellum 2011;10:184–98.
   PubMed Web of Science ®Google Scholar
• Soong B, Paulson HL. Spinocerebellar ataxias: an update. Curr Opin Neurbiol 2007;20:438–46.
   Web of Science ®Google Scholar
• Calabrese V, Guagliano E, Sapienza M, Mancuso C, Butterfield DA, Stella AM. Redox regulation of cellular stress response in neurodegenerative disorders. Ital J Biochem 2006;55(3–4):263–82.
   PubMedGoogle Scholar
• Yokota T, Igarashi K, Uchihara T, Jishage K, Tomita H, Inaba A, et al. Delayed-onset ataxia in mice lacking α-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. PNAS. 2001;98(26):15185.
   PubMed Web of Science ®Google Scholar
• Velásquez-Pérez L, Rodríguez-Chanfrau J, García-Rodríguez JC, Sánchez-Cruz G, Aguilera-Rodríguez R, Rodríguez-Labrada R, et al. Oral zinc sulphate supplementation for six months in SCA2 patients: a randomized, double-blind, placebo-controlled trial. Neurochem Res 2011;36:1793–800.
   PubMed Web of Science ®Google Scholar